Cargando…

S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis

OBJECTIVE: To assess S-1 and 5-fluorouracil (5-FU)-related adverse events in patients with advanced gastric cancer and provide focused health care approaches to improve patient compliance and quality of survival. METHODS: The PubMed, Web of Science, Medline, Cochrane Library, EMbase, SinoMed, Wan Fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qingqing, Xu, Jiajia, Ke, Jingshu, Zhang, Ziye, Chu, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420378/ https://www.ncbi.nlm.nih.gov/pubmed/37566608 http://dx.doi.org/10.1371/journal.pone.0290003

Ejemplares similares

Meta-Analysis of Capecitabine versus 5-Fluorouracil in Advanced Gastric Cancer
por: Wu, Zhongliang, et al.
Publicado: (2023)

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
por: Li, Bo, et al.
Publicado: (2019)

5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
por: Deac, Andrada-Larisa, et al.
Publicado: (2023)

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
por: Cho, Eun Kyung, et al.
Publicado: (2002)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Advanced Gastric Carcinoma Chemotherapy with Cisplatin, Mitomycin C, BCNU, and 5-Fluorouracil in Combination
por: Kim, Re Hwe, et al.
Publicado: (1987)

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer
por: Wang, Qinchuan, et al.
Publicado: (2020)

Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients
por: Ge, Jie, et al.
Publicado: (2021)

Upregulation of ECT2 Predicts Adverse Clinical Outcomes and Increases 5-Fluorouracil Resistance in Gastric Cancer Patients
por: Zhang, Hua, et al.
Publicado: (2021)

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis
por: Wang, Liang, et al.
Publicado: (2017)

Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023)

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis
por: Guo, Chang-Ying, et al.
Publicado: (2019)

5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer
por: Biagioni, Alessio, et al.
Publicado: (2020)

Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
por: Chi, K. H., et al.
Publicado: (1998)

Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer
por: Min, Young Joo, et al.
Publicado: (2004)

Advanced Gastric Cancer Associated with Disseminated Intravascular Coagulation Successfully Treated with 5-fluorouracil and Oxaliplatin
por: Lee, Dong Seok, et al.
Publicado: (2013)

Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database
por: Zeng, Yifan, et al.
Publicado: (2021)

Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma
por: GUO, XU-FENG, et al.
Publicado: (2015)

Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
por: Hwang, Junyl, et al.
Publicado: (2008)

Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review
por: Copley-Merriman, Catherine, et al.
Publicado: (2018)

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

Effects of non-pharmacological interventions on patients with sarcopenic obesity: A meta-analysis
por: Xu, Jiajia, et al.
Publicado: (2023)

Mechanisms and biomarkers of immune-related adverse events in gastric cancer
por: Ding, Ping’an, et al.
Publicado: (2023)

Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase
por: Nakamura, Ayako, et al.
Publicado: (2013)

Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil
por: Coelho, Rafael C., et al.
Publicado: (2019)

Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer
por: Huang, Xingxing, et al.
Publicado: (2022)

Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis
por: Chen, Xiao-Dong, et al.
Publicado: (2016)

Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment
por: Xu, Jing-Li, et al.
Publicado: (2022)

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen
por: Cascinu, S, et al.
Publicado: (2002)

High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
por: Highley, M. S., et al.
Publicado: (1993)

Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status
por: Tan, Yuting, et al.
Publicado: (2014)

Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil
por: Charkviani, Mariam, et al.
Publicado: (2020)

5-Fluorouracil-related Cardiotoxicity with Coronary Vasospasms
por: Faheem, Beenish, et al.
Publicado: (2022)

Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo
por: LIAO, FEI, et al.
Publicado: (2013)

Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer
por: Tamura, Takao, et al.
Publicado: (2011)

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016)

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
por: Zambatis, Charalambos, et al.
Publicado: (1998)

Recent advances in electrochemical determination of anticancer drug 5-fluorouracil
por: Dodevska, Totka, et al.
Publicado: (2023)

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer
por: Park, Se Hoon, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_2s0hv4at1n5kpm3unln2h0i4tg